This transaction
This share transferThe voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.
Manufacture and sale of pharmaceuticals, quasi-drugs, cosmetics, medical devices, food products, beverages and other products
The impact on the full-year consolidated earnings forecast for the fiscal year ending March 2027 is currently under review, and we will make a timely announcement once the details are finalized. In addition, revenue from the share transfer is expected to be recognized in the fiscal year ending March 2028, when our voting rights ownership ratio in DSHC will be 30%.
| Item | Details |
|---|---|
| Transaction name | This share transfer |
| Counterparty name | Suntory Holdings Limited |
| Name of the Subject Company | Daiichi Sankyo Healthcare Co., Ltd. |
| Business Description of the Subject Company | Manufacture and sale of pharmaceuticals, quasi-drugs, cosmetics, medical devices, food products, beverages and other products |
| Location of the Subject Company | Chuo-ku, Tokyo |
| Capital Stock of the Subject Company | ¥100 million |
| Date of Establishment of the Subject Company | 16 December 2005 |
| Net Sales of the Subject Company | Fiscal year ended March 2025: ¥76,049 million |
| Operating Profit of the Subject Company | Fiscal year ended March 2025: ¥12,922 million |
| Net Income of the Subject Company | Fiscal year ended March 2025: ¥8,997 million |
| Net Assets of the Subject Company | Fiscal year ended March 2025: ¥69,321 million |
| Acquisition price | ¥246,500 million (expected transfer price) |
| Number of shares acquired | 10,000 shares (10,000 voting rights) |
| Voting rights ownership percentage | Before 100% → after 0% |
| Impact on Business Performance | The impact on the full-year consolidated earnings forecast for the fiscal year ending March 2027 is currently under review, and we will make a timely announcement once the details are finalized. In addition, revenue from the share transfer is expected to be recognized in the fiscal year ending March 2028, when our voting rights ownership ratio in DSHC will be 30%. |
| Date of board resolution | 31 March 2026 |
| Contract Date | 15 April 2026 |
| Execution Date / Effective Date | 1 June 2026 (expected; 30% of the shares will be transferred, resulting in a 70% voting rights ownership ratio), 1 June 2027 (expected; shares will be transferred, resulting in a 30% voting rights ownership ratio), and 1 June 2029 (expected; all remaining shares held will be transferred) |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Daiichi Sankyo determined that advancing the growth of Daiichi Sankyo Healthcare by leveraging the strong business foundation Suntory Holdings has built in the beverage, food and health foods businesses is appropriate. Daiichi Sankyo also states that it will concentrate its management resources on its innovative pharmaceuticals business.